[Clinical and biochemical evaluation of the administration of growth hormone].
Ten children with isolated growth hormone deficiency were treated for 1 year with 0.5 UI/kg week with Somatrem (recombinant human growth hormone), given as intramuscular injections three times weekly. Before treatment the children had a chronological age of 7-12.4 years (mean 10.4 years), with a bone age at least 25% below the chronological age. There was no radiological evidence of an intra or suprasellar mass in any child, and no response to provocative growth hormone tests (with exercise or arginine-insulin injection). Informed written consent for treatment was obtained from the parents of each child. Clinical signs were registered every month; triiodothyronine, thyroxine, thyrotropine, glucose, urea, creatinine, blood cells count, and hemoglobine, glycosylated hemoglobine, glutamic-piruvic and glutamic-oxalacetic transaminases, alkaline phosphatase, anti-human growth hormone and, E. coli antibodies, insulin like growth factor 1, and bone age were assessed every 3 months. The mean height velocity was 0.27 +/- 0.1 cm/month before treatment, and increased throughout treatment to a value of 0.62 +/- 0.16 cm/month after 12 months. Within the first year eight of the 10 children had a height increase of 8.4 +/- 0.98 cm. The other two children showed no significant difference; one of them with a very low socioeconomic status, and the other developed typhoid fever. All of the children showed an advance in bone age, but none reached a bone age appropriate for their chronological age; without modifications in the laboratory parameters. Insulin like growth factor 1 increased in 9 children. Pain at the injection site was the only side effect reported.
Mendoza-Morfin
F
F
Departamento de Endocrinología Pediátrica, Hospital General, Centro Médico La Raza, Instituto Mexicano del Seguro Social, México, D.F.
Cárdenas-Tirado
H
H
D000917:Antibody Formation; D002648:Child; D005260:Female; D006130:Growth Disorders / Q000097:blood* / Q000188:drug therapy*; D013006:Growth Hormone / Q000031:analogs & derivatives* / Q000276:immunology / Q000627:therapeutic use; D019382:Human Growth Hormone; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000276:immunology / Q000627:therapeutic use
D011994:Recombinant Proteins; D019382:Human Growth Hormone; D013006:Growth Hormone
Evaluación clínica y bioquímica de la administración de hormona de crecimiento.